➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Dow
Johnson and Johnson
McKinsey
Medtronic
AstraZeneca

Last Updated: August 8, 2020

DrugPatentWatch Database Preview

ENBREL Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for ENBREL

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Rochester General HospitalPhase 1
RTI InternationalPhase 1
Nova Southeastern UniversityPhase 1

See all ENBREL clinical trials

Recent Litigation for ENBREL

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
Celgene Corporation v. Mylan Pharmaceuticals Inc.2020-01-03
CELGENE CORPORATION v. MYLAN PHARMACEUTICALS INC.2019-12-31
CELGENE CORPORATION v. HETERO LABS LIMITED2019-07-16

See all ENBREL litigation

PTAB Litigation
PetitionerDate
2018-08-03
2014-11-06
2013-08-15

See all ENBREL litigation

Pharmacology for ENBREL

Company Disclosures: US Patents for ENBREL

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Immunex ENBREL etanercept VIAL; SUBCUTANEOUS 103795 001 1998-11-02   Start Trial Immunex Corporation (Seattle, WA) 2012-03-07 RX Orphan company
Immunex ENBREL etanercept VIAL; SUBCUTANEOUS 103795 001 1998-11-02   Start Trial Immunex Corporation (Seattle, WA) 2014-02-25 RX Orphan company
Immunex ENBREL etanercept VIAL; SUBCUTANEOUS 103795 001 1998-11-02   Start Trial Immunex Corporation (Seattle, WA) 2009-09-05 RX Orphan company
Immunex ENBREL etanercept VIAL; SUBCUTANEOUS 103795 001 1998-11-02   Start Trial Immunex Corporation (Seattle, WA) 2009-09-11 RX Orphan company
Immunex ENBREL etanercept VIAL; SUBCUTANEOUS 103795 001 1998-11-02   Start Trial 2009-09-05 RX Orphan company
Immunex ENBREL etanercept VIAL; SUBCUTANEOUS 103795 001 1998-11-02   Start Trial Immunex Corporation (Seattle, WA) 2009-09-05 RX Orphan company
Immunex ENBREL etanercept VIAL; SUBCUTANEOUS 103795 001 1998-11-02   Start Trial Immunex Corporation (Thousand Oaks, CA) 2019-04-19 RX Orphan company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for ENBREL

These patents were identified by searching patent claims

Supplementary Protection Certificates for ENBREL

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C01409016/01 Switzerland   Start Trial PRODUCT NAME: DENOSUMABUM; REGISTRATION NO/DATE: SWISSMEDIC 60210 03.08.2010
122010000047 Germany   Start Trial PRODUCT NAME: DENOSUMAB; REGISTRATION NO/DATE: EU/1/10/618/001-004 20100526
C300728 Netherlands   Start Trial PRODUCT NAME: IBRUTINIB OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT ERVAN; REGISTRATION NO/DATE: EU/1/14/945 20141021
PA2017038 Lithuania   Start Trial PRODUCT NAME: SARILUMABAS; REGISTRATION NO/DATE: EU/1/17/1196 20170623
122016000093 Germany   Start Trial PRODUCT NAME: LBRUTINIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/14/945 20160526
301035 Netherlands   Start Trial PRODUCT NAME: UPADACITINIB OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/19/1404 20191218
1090038-9.L Sweden   Start Trial PRODUCT NAME: DENOSUMAB; REG. NO/DATE: EU/1/10/618/001 20100526
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
Johnson and Johnson
Express Scripts
AstraZeneca
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.